Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

facturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to fund operations through the primary endpoint analysis of its Phase 3 clinical registration trial progress and timing of clinical trials for Specifid, including difficulties or delays in development, testing, manufacturing and marketing Specifid or Favrille's other product candidates; delays in the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for Specifid or Favrille's other product candidates and the timing of any such approvals, including whether a clinically meaningful response improvement can serve as the basis for accelerated approval of Specifid and whether it will receive expedited review as a result of the Fast Track designation; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of Specifid for use in clinical trials and, if Specifid receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using Specifid; potential delays in patient enrollme
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... Proove Biosciences , a commercial and research ... posters at the Annual Clinical Genetics Meeting in Salt ... hosted at the Salt Palace Convention Center and attracted ... genomic professionals on breakthrough advances in clinical genetics. , ... Role of DAT1 in Risk of Insomnia on Thursday, ...
(Date:4/1/2015)... 2015 Research and Markets ( ... "Forensic Technologies and Services - Global Strategic ... This report analyzes the US market for ... the following Segments: Forensic Databases, Forensic Consulting and ... Annual estimates and forecasts are provided for ...
(Date:4/1/2015)... NEW YORK CITY and LONDON ... provider of market research reports and solutions, MarketResearch.com is pleased ... 2015 will be a year of market growth and opportunity ... a stem cell company or cord blood bank, competing in ... analyze market conditions, predict industry trends, and act on market ...
(Date:3/31/2015)... 2015 CytoSorbents Corporation (NASDAQ CM: CTSO), ... to treat critically-ill and cardiac surgery patients in ... reports financial results for the fiscal year ending ... product revenues were a record $3.1M, an increase ... revenues of $0.8M Highlights for the Year Ending ...
Breaking Biology Technology:Proove Biosciences Presents Research Studies at Annual Clinical Genetics Meeting 2015 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 2Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 3Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 4Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 5Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 6Forensic Technologies and Services - Global Strategic Business Report 2015-2020: Rise in Terrorist Bombings Sharpens the Business Case for Explosives Forensics 7MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 2MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 3MarketResearch.com: "Blockbuster" Year for Stem Cells Creates Market Opportunities, Says BioInformant Worldwide Report 4CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11
... Ltd.,(SWX: ARPN) today announced that Dr Jurgen Raths will ... Raths commands extensive,knowledge in the commercialisation of drugs for ... built and lead the European,Critical Care sales, medical and ... At the Annual General Meeting of 7 May, ...
... ,Exelixis, Inc. (Nasdaq: EXEL ) announced today that ... Exelixis, will present at the,Morgan Stanley Global Healthcare Unplugged ... 30, 2008. Dr. Scangos will discuss updates to,the company,s ... be webcast and may be accessed in the Event,Calendar ...
... Inc. (Nasdaq: IDIX ) announced today that ... upcoming Morgan Stanley Global,Healthcare Unplugged Conference on Wednesday, ... Ritz Carlton in Key Biscayne, Florida., The ... can be,accessed under "Calendar of Events" in the ...
Cached Biology Technology:Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 2Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 3Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company 4
(Date:4/1/2015)... April 1, 2015   Medisafe ™, the leading ... across iOS and Android smartphones ... biofeedback into the platform to allow patients to track ... the first time, patients will be able to visualize ... impacts important biometrics, such as glucose levels and blood ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... be the impact of the next green revolution on global ... climate change? To what extent can biofuels help make America ... be discussed at the International Annual Meetings of the American ... and Soil Science Society of America (SSSA), Oct. 31-Nov. 3 ...
... NY, October 28, 2010Mary Ann Liebert, Inc. announces the ... area of systems neuroscience, Brain Connectivity . This ... source of cutting-edge basic and clinical neuroscience research aimed ... the brain and how these connections are altered by ...
... by Lupus Research Institute-funded investigator Emily Baechler Gillespie, PhD, at ... clinical laboratory for development and could soon result in a ... to determine when a lupus flare is imminent. ... way to predict when a person with systemic lupus is ...
Cached Biology News:Media alert: Agronomists, crop and soil scientists to convene in Long Beach 2New Brain Connectivity journal captures latest advances in neuroscience research 2New clinical test to predict lupus flares moves closer to the market 2